Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation and expansion study of GSK3326595 in advanced solid tumors and non-Hodgkin lymphoma
NL-OMON53127Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pemrametostat and pembrolizumab in Nonhematologic neoplasms, non-Hodgkin lymphoma (NHL), breast cancer and 8 more (3 arms), sponsored by GSK. Started Feb 2017; status: completed.
02
Drugs
pemrametostatpembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)breast cancertransitional cell carcinoma (TCC)glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON53127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53127.